BE study Design for Ri­va­rox­aban 20 mg [Design Issues]

posted by Tricky TAB – Bangladesh, 2022-07-04 13:33 (633 d 05:53 ago) – Posting: # 23103
Views: 2,196

Hello!

The Design for Rivaroxaban 20 mg BE Study stated by US-FDA is as follows:

Single-dose, two-treatment, two-sequence, four-period, fully replicate crossover

Is it possible to go with Single-dose, two-treatment, two-sequence, two-period crossover study design?

Thank You!


Edit: Category changed; see also this post #1. Guidance linked. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
22,957 posts in 4,819 threads, 1,638 registered users;
75 visitors (0 registered, 75 guests [including 9 identified bots]).
Forum time: 18:27 CET (Europe/Vienna)

Nothing shows a lack of mathematical education more
than an overly precise calculation.    Carl Friedrich Gauß

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5